A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
NCT06015308
Active Not Recruiting
This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD). The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis \[Tdap\]) and Pneumovax 23 (PPSV) vaccines in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Clinical Research Center of Alabama - Homewood- Site Number : 8401101, Birmingham, Alabama +56 locations
Conditions: Dermatitis Atopic
Register for Updates
Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
NCT05973006
Completed
This study is a large-scale investigation (Phase 3) into a new booster shot designed specifically for teenagers. The booster targets a particular variant of COVID-19, Omicron XBB.1.5. The main focus is on safety: researchers want to see if this new booster is safe for teenagers who have already received two doses of the Pfizer or Moderna mRNA COVID-19 vaccines. To ensure a fair comparison, the study will use a double-blind approach. This means two groups of teenagers will receive booster shots,... Read More
Gender:
ALL
Ages:
Between 11 years and 18 years
Trial Updated:
06/25/2025
Locations: Alfa Medical Research, Davie, Florida +19 locations
Conditions: COVID-19
Register for Updates
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
NCT05875701
Completed
This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster doses following a series of primary and booster doses of authorized/approved mRNA vaccines followed by a single booster dose of NVX-CoV2373 in the Novavax 2019nCoV-307 study (NCT05463068).
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
06/25/2025
Locations: Benchmark Research, Austin, Texas +4 locations
Conditions: COVID-19
Register for Updates
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
NCT05827978
Completed
This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Pinnacle Research Group, Anniston, Alabama +102 locations
Conditions: Seasonal Influenza
Register for Updates
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
NCT06097273
Completed
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) vaccines, in 2 independent age-group sub-study cohorts, healthy adults 65 years and older (Cohort A) and healthy adults 50 to \<65 years of age (Cohort B).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/23/2025
Locations: Pinnacle Research Group-409 E 10th St, Anniston, Alabama +145 locations
Conditions: SARS-CoV-2, Influenza
Register for Updates
A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
NCT06361875
Completed
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV- standard dose (SD), QIV- high dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Long Beach Clinical Trials Site Number : 8400013, Long Beach, California +19 locations
Conditions: Influenza Immunization
Register for Updates
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT05920798
Recruiting
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalphaDC) with pembrolizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer (collectively known as ovarian cancer) that that has come back (after a period of improvement) (recurrent). Ovarian cancer is the most lethal gynecologic malignancy in the United States. While the majority of patients achieve a remission... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Carcinosarcoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinosarcoma
Register for Updates
CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera
NCT03705585
Recruiting
This is an open-label, non-randomized study. The purpose of this study is to better understand how vaccines against typhoid fever and cholera affect the normal immune system and bacteria in the intestine. Patients having standard-of-care endoscopies (colonoscopy and/or esophagogastroduodenoscopy (EGD)) will be divided into 3 groups: Group 1: Vivotif typhoid vaccination and/or Vaxchora cholera vaccination then endoscopy Group 2: Endoscopy, then Vivotif typhoid vaccination and/or Vaxchora cholera... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore, Maryland
Conditions: Typhoid and/or Cholera Vaccination
Register for Updates
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
NCT06821061
Recruiting
The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Anaheim Clinical Trials, LLC, Anaheim, California +30 locations
Conditions: Influenza, COVID-19 (Coronavirus Disease 2019)
Register for Updates
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
NCT06782932
Recruiting
The purpose of this study is to determine the optimal dose of AGEN2373 that is safe when given in combination with balstilimab and Pancreatic GVAX Whole Cell Vaccine and evaluate the safety and clinical activity of balstilimab and AGEN2373 in combination with GVAX (Arm 1) or mKRASvax (Arm 2) in surgically resectable pancreatic adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Pancreatic Cancer
Register for Updates
Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults
NCT07002060
Recruiting
The purpose of this study is to assess the safety of vYF (investigational vaccine) compared to the safety of YF-VAX (YF licensed vaccine) in adults aged 18 years up to 60 years. Study details include: * The study duration will be up to approximately 6 months. * One single dose of the study intervention (vYF or YF-VAX) will be administered subcutaneously at the 1st visit. * The visit(V) frequency will be Day(D) 01 (V01) and D29 (V02). Two telephone calls will be planned at D15 and Month(M)6. N... Read More
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
06/16/2025
Locations: Velocity Clinical Research-New Orleans- Site Number : 8400004, New Orleans, Louisiana +3 locations
Conditions: Yellow Fever Immunization
Register for Updates
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
NCT02432378
Terminated
This study will evaluate the immunologic and potential clinical effectiveness of intensive locoregional sequential intraperitoneal (IP) cisplatin (IPC) with intravenous (iv) paclitaxel followed by peritoneal infusion of a chemokine modulatory (CKM) regimen composed of a cocktail of IP rintatolimod and interferon-alpha (IFNα) for patients with advanced stage ovarian cancer (III-IV) at primary neoadjuvant setting. In the safety phase I phase, we determined the tolerable dose of IPC-CKM. In this p... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: UPMC CancerCenter at Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania +1 locations
Conditions: Cancer of Ovary, Cancer of the Ovary, Neoplasms, Ovarian, Ovarian Cancer, Ovary Cancer, Ovary Neoplasms
Register for Updates